Fight HCM with
Felycin®-CA1

(sirolimus delayed-release tablets)

Felycin-CA1 is the first and only medication conditionally approved by the FDA for for the management of ventricular hypertrophy in cats with subclinical hypertrophic cardiomyopathy (HCM).

Now you can offer early intervention to your feline patients with subclinical HCM.

We studied it so you can prescribe it with confidence

In the RAPACAT study, thirty-six cats with subclinical HCM were administered Felycin-CA1 or a placebo. Cats treated with Felycin-CA1 had a significantly lower left ventricular maximal wall thickness, with an average reduction of 0.17 mm in comparison to 0.94 mm increase for cats receiving placebo.1

The drug also underwent extensive safety studies, and Felcyin-CA1’s once-weekly dosing regimen demonstrated a favorable safety profile.

maximal-wall-thickness-graph

Felycin-CA1’s mode of action

What veterinarians are saying about Felycin-CA1

vimeo-thumbnail
HCM: A new standard of care video
vimeo-thumbnail (1)
Clinically proven HCM Management Video
vimeo-thumbnail (2)
Hope for HCM Cats Video

Ready to prescribe Felycin-CA1?

 

Join the fight against HCM. To order Felycin-CA1, contact your local representative or authorized distributor.

svgexport-1 (2)

If you’re not diagnosing HCM in 1 of every 7 cats you see, you may be missing a chance to intervene.

Your Experience Could Shape the Future of Feline Care

 

Have you treated a cat with Felycin-CA1? Share your success story and help other clinics see the difference early intervention can make.

Felycin-CA1 FAQ

References
1 Fuentes VL, Abbott J, Chetboul V, et al. ACVIM consensus statement guidelines for the classification, diagnosis, and management of cardiomyopathies in cats. JVIM 2020;34:1062-1077.
2 Kittleson MD, Cote E. The feline cardiomyopathies: Hypertrophic cardiomyopathy. JFMS 2021;23:1028-1051.